Allogeneic hematopoietic cell transplantation with sequential conditioning regimen in relapsed refractory acute myeloid leukemia
Carles Tolosa-Ridao,María Suárez-Lledó,Carlos Jiménez-Vicente,Albert Cortés-Bullich,Beatriz Merchan,Alexandra Martínez-Roca,Francisca Guijarro,Sandra Castaño-Díez,Laura Rosiñol,Francesc Fernández-Avilés,Carmen Martínez,Marina Díaz-Beya,Jordi Esteve,Montserrat Rovira,María Queralt Salas
DOI: https://doi.org/10.1038/s41409-024-02310-6
2024-05-23
Bone Marrow Transplantation
Abstract:Treatment landscape for acute myeloid leukemia (AML) has witnessed notable advances in recent years, resulting in improves outcomes for a considerable number of patients [1]. Despite these strides, 10–20% of cases fail to achieve morphological remission (CR) following induction regimens [2]. Moreover, even among those achieving an initial CR, early disease relapse presents a formidable challenge, with only a minority of patients benefiting from salvage regimens [3, 4]. Allogeneic hematopoietic cell transplantation (allo-HCT) emerges as a potentially curative option for individuals with relapsed/refractory (R/R) AML, yet its efficacy remains a topic of debate [2, 5]. Different studies have suggested that using sequential-based conditioning might offer promising results to patients with R/R AML [2]. In 2021, the Acute Leukemia Working Party (ALWP) of the EBMT examined the outcomes of patients undergoing allo-HCT in patients with R/R AML and using six different drug combinations of sequential-based conditioning regimens between 2000 and 2017. This registry-based retrospective analysis included a very large cohort of 2132 patients, being one of the largest studies conducted in this field. Interestingly, the observed rates of disease remission after allo-HCT were up to 74.7%. However, at 2-years, the reported rates of disease relapse (CIR) were up to 44.4%, and the observed 2-year overall survival (OS), leukemia-free survival (RFS), and non-relapse mortality (NRM) were, respectively, 30.3%, 35.9%, and 25.3% [1]. Although using this transplant strategy demonstrated to be effective on achieving an early disease remission after the stem cell infusion, the limited outcomes of patients at 2-years suggested that more efficient and less toxic transplant platform strategies are still needed for patients with R/R AML. Furthermore, prognostic factors for transplantation success in patients with R/R AML remains controversial [6], although certain factors as the absence of blasts in blood and bone marrow, and primary induction response have shown associations with better outcomes [7, 8].
oncology,immunology,hematology,transplantation